Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cerevel Therapeutics Hldg Inc (CERE)

Cerevel Therapeutics Hldg Inc (CERE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cerevel Therapeutics Hldg Inc 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 USA

www.cerevel.com P: 844-304-2048

Description:

Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics Inc., formerly known as Acquisition Corp II, is headquartered in Boston.

Key Statistics

Overview:

Market Capitalization, $K 7,530,120
Enterprise Value, $K 7,113,650
Shares Outstanding, K 182,195
Annual Sales, $ 0 K
Annual Net Income, $ -432,840 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -131,910 K
EBIT, $ -490,370 K
EBITDA, $ -504,440 K
60-Month Beta 1.46
% of Insider Shareholders 5.10%
% of Institutional Shareholders 87.73%
Float, K 172,903
% Float 94.90%
Short Volume Ratio 0.25

Growth:

1-Year Return 24.90%
3-Year Return 215.02%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.73 on 05/08/24
Next Earnings Date N/A
Earnings Per Share ttm -1.97
EPS Growth vs. Prev Year -8.96%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CERE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -98.94%
Return-on-Assets % -45.07%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 13.44
Book Value/Share 3.10
Interest Coverage -39.90
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar